Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Redmile Group, Llc Purchases 400,000 Shares

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Redmile Group, Llc bought 400,000 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $6,800,000.00. Following the completion of the acquisition, the insider directly owned 1,182,854 shares in the company, valued at approximately $20,108,518. This trade represents a 51.10% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Attovia Therapeutics Price Performance

NASDAQ ATTO opened at $20.17 on Friday. Attovia Therapeutics, Inc. has a 12 month low of $18.64 and a 12 month high of $22.79.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Attovia Therapeutics stock. BlackRock Inc. raised its position in Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% during the second quarter, according to its most recent filing with the SEC. The firm owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent filing with the SEC.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.